세계의 RSV 진단 시장 : 시장 규모 분석 - 제품별, 방법별, 최종 사용자별, 지역별 예측(2025-2035년)

The Global RSV Diagnostics Market, valued at approximately USD 6.27 billion in 2024, is projected to advance at a robust CAGR of 5.81% between 2025 and 2035. Respiratory Syncytial Virus (RSV) is a pervasive pathogen that significantly impacts pediatric, geriatric, and immunocompromised populations, causing a substantial burden on healthcare systems worldwide. The rising global awareness of RSV's severe clinical implications, coupled with intensified initiatives to strengthen early detection capabilities, has catapulted the demand for advanced diagnostic solutions. Modern RSV diagnostic technologies, particularly molecular-based platforms and high-sensitivity immunoassays, are increasingly being adopted in both hospital and point-of-care settings to reduce diagnostic turnaround times, improve patient triage, and facilitate timely intervention. The growing integration of automation and AI-driven interpretation tools into RSV diagnostic workflows is further enhancing accuracy and scalability, positioning the market for sustained expansion.

The surge in RSV incidence rates-exacerbated by seasonal outbreaks and fluctuating immunity patterns-has pushed laboratories and clinical facilities to upgrade testing capabilities. This trend is particularly evident in regions experiencing post-pandemic respiratory infection rebounds, where timely detection is critical to mitigating hospital overcrowding. According to data from the U.S. Centers for Disease Control and Prevention, RSV-associated hospitalizations in older adults surged significantly in recent winters, highlighting the urgent need for scalable and reliable testing infrastructure. Furthermore, advances in multiplex testing, which allow simultaneous screening for RSV alongside influenza and SARS-CoV-2, are expanding the value proposition of RSV diagnostics for both healthcare providers and patients. However, market growth could face headwinds from cost constraints in low-resource healthcare settings, as well as limited availability of trained personnel to operate advanced diagnostic platforms.

Regionally, North America currently commands a dominant share of the RSV diagnostics market, bolstered by strong public health surveillance programs, well-developed healthcare infrastructure, and proactive adoption of molecular diagnostics. The region also benefits from extensive R&D investment and frequent product launches by leading diagnostic manufacturers. Europe follows closely, driven by government-backed screening programs, strong adoption of point-of-care testing, and rising RSV awareness among clinicians and the general public. In contrast, Asia Pacific is expected to be the fastest-growing market through 2035, fueled by expanding healthcare access, rising pediatric population sizes, and government initiatives to strengthen infectious disease detection networks in countries like China, India, and Japan. Meanwhile, emerging markets in Latin America and the Middle East & Africa are gaining momentum as they invest in upgrading laboratory capabilities and increasing RSV testing coverage to address both seasonal and epidemic surges.

Major market player included in this report are:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• BioMerieux SA
• QuidelOrtho Corporation
• Siemens Healthineers AG
• BD (Becton, Dickinson and Company)
• Hologic, Inc.
• PerkinElmer Inc.
• Meridian Bioscience, Inc.
• Luminex Corporation
• Cepheid (a Danaher company)
• DiaSorin S.p.A.
• GenMark Diagnostics, Inc.

Global RSV Diagnostics Market Report Scope:

• Historical Data - 2023, 2024
• Base Year for Estimation - 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Product:

• Kits and Assays
• Instruments

By Method:

• Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA)
• Molecular Diagnostic

By End User:

• Hospitals & Clinics
• Clinical Laboratories
• Homecare

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global RSV Diagnostics Market Report Scope & Methodology

• 1.1. Research Objective
• 1.2. Research Methodology
  • 1.2.1. Forecast Model
  • 1.2.2. Desk Research
  • 1.2.3. Top Down and Bottom-Up Approach
• 1.3. Research Attributes
• 1.4. Scope of the Study
  • 1.4.1. Market Definition
  • 1.4.2. Market Segmentation
• 1.5. Research Assumption
  • 1.5.1. Inclusion & Exclusion
  • 1.5.2. Limitations
  • 1.5.3. Years Considered for the Study

Chapter 2. Executive Summary

• 2.1. CEO/CXO Standpoint
• 2.2. Strategic Insights
• 2.3. ESG Analysis
• 2.4. Key Findings

Chapter 3. Global RSV Diagnostics Market Forces Analysis

• 3.1. Market Forces Shaping The Global RSV Diagnostics Market (2024-2035)
• 3.2. Drivers
  • 3.2.1. Rising incidence of RSV infections and increasing demand for rapid, accurate diagnostics
  • 3.2.2. Technological advancements-molecular platforms, multiplex assays, automation and AI-assisted interpretation enhancing throughput and accuracy
• 3.3. Restraints
  • 3.3.1. High capital expenditure for advanced molecular platforms and recurring consumables costs limiting adoption in low-resource settings
  • 3.3.2. Shortage of trained laboratory personnel and regulatory hurdles delaying product launches in certain regions
• 3.4. Opportunities
  • 3.4.1. Expansion of multiplex respiratory panels (RSV/Influenza/SARS-CoV-2) and integrated testing workflows offering cross-selling and recurring revenue streams
  • 3.4.2. Growth of point-of-care and homecare testing, plus government-led surveillance programs in emerging markets

Chapter 4. Global RSV Diagnostics Industry Analysis

• 4.1. Porter's 5 Forces Model
  • 4.1.1. Bargaining Power of Buyer
  • 4.1.2. Bargaining Power of Supplier
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Forecast Model (2024-2035)
• 4.3. PESTEL Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top Investment Opportunities
• 4.5. Top Winning Strategies (2025)
• 4.6. Market Share Analysis (2024-2025)
• 4.7. Global Pricing Analysis And Trends 2025
• 4.8. Analyst Recommendation & Conclusion

Chapter 5. Global RSV Diagnostics Market Size & Forecasts by Product 2025-2035

• 5.1. Market Overview
• 5.2. Global RSV Diagnostics Market Performance - Potential Analysis (2025)
• 5.3. Kits and Assays
  • 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 5.3.2. Market size analysis, by region, 2025-2035
• 5.4. Instruments
  • 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 5.4.2. Market size analysis, by region, 2025-2035

Chapter 6. Global RSV Diagnostics Market Size & Forecasts by Method 2025-2035

• 6.1. Market Overview
• 6.2. Global RSV Diagnostics Market Performance - Potential Analysis (2025)
• 6.3. Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA)
  • 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.3.2. Market size analysis, by region, 2025-2035
• 6.4. Molecular Diagnostic
  • 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 6.4.2. Market size analysis, by region, 2025-2035

Chapter 7. Global RSV Diagnostics Market Size & Forecasts by End User 2025-2035

• 7.1. Market Overview
• 7.2. Global RSV Diagnostics Market Performance - Potential Analysis (2025)
• 7.3. Hospitals & Clinics
  • 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 7.3.2. Market size analysis, by region, 2025-2035
• 7.4. Clinical Laboratories
  • 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 7.4.2. Market size analysis, by region, 2025-2035
• 7.5. Homecare
  • 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
  • 7.5.2. Market size analysis, by region, 2025-2035

Chapter 8. Global RSV Diagnostics Market Size & Forecasts by Region 2025-2035

• 8.1. Global RSV Diagnostics Market, Regional Market Snapshot
• 8.2. Top Leading & Emerging Countries
• 8.3. North America RSV Diagnostics Market
  • 8.3.1. U.S. RSV Diagnostics Market
    • 8.3.1.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.3.1.2. End User breakdown size & forecasts, 2025-2035
  • 8.3.2. Canada RSV Diagnostics Market
    • 8.3.2.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.3.2.2. End User breakdown size & forecasts, 2025-2035
• 8.4. Europe RSV Diagnostics Market
  • 8.4.1. UK RSV Diagnostics Market
    • 8.4.1.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.4.1.2. End User breakdown size & forecasts, 2025-2035
  • 8.4.2. Germany RSV Diagnostics Market
    • 8.4.2.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.4.2.2. End User breakdown size & forecasts, 2025-2035
  • 8.4.3. France RSV Diagnostics Market
    • 8.4.3.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.4.3.2. End User breakdown size & forecasts, 2025-2035
  • 8.4.4. Spain RSV Diagnostics Market
    • 8.4.4.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.4.4.2. End User breakdown size & forecasts, 2025-2035
  • 8.4.5. Italy RSV Diagnostics Market
    • 8.4.5.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.4.5.2. End User breakdown size & forecasts, 2025-2035
  • 8.4.6. Rest of Europe RSV Diagnostics Market
    • 8.4.6.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.4.6.2. End User breakdown size & forecasts, 2025-2035
• 8.5. Asia Pacific RSV Diagnostics Market
  • 8.5.1. China RSV Diagnostics Market
    • 8.5.1.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.5.1.2. End User breakdown size & forecasts, 2025-2035
  • 8.5.2. India RSV Diagnostics Market
    • 8.5.2.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.5.2.2. End User breakdown size & forecasts, 2025-2035
  • 8.5.3. Japan RSV Diagnostics Market
    • 8.5.3.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.5.3.2. End User breakdown size & forecasts, 2025-2035
  • 8.5.4. Australia RSV Diagnostics Market
    • 8.5.4.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.5.4.2. End User breakdown size & forecasts, 2025-2035
  • 8.5.5. South Korea RSV Diagnostics Market
    • 8.5.5.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.5.5.2. End User breakdown size & forecasts, 2025-2035
  • 8.5.6. Rest of APAC RSV Diagnostics Market
    • 8.5.6.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.5.6.2. End User breakdown size & forecasts, 2025-2035
• 8.6. Latin America RSV Diagnostics Market
  • 8.6.1. Brazil RSV Diagnostics Market
    • 8.6.1.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.6.1.2. End User breakdown size & forecasts, 2025-2035
  • 8.6.2. Mexico RSV Diagnostics Market
    • 8.6.2.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.6.2.2. End User breakdown size & forecasts, 2025-2035
• 8.7. Middle East and Africa RSV Diagnostics Market
  • 8.7.1. UAE RSV Diagnostics Market
    • 8.7.1.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.7.1.2. End User breakdown size & forecasts, 2025-2035
  • 8.7.2. Saudi Arabia (KSA) RSV Diagnostics Market
    • 8.7.2.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.7.2.2. End User breakdown size & forecasts, 2025-2035
  • 8.7.3. South Africa RSV Diagnostics Market
    • 8.7.3.1. Product/Method breakdown size & forecasts, 2025-2035
    • 8.7.3.2. End User breakdown size & forecasts, 2025-2035

Chapter 9. Competitive Intelligence

• 9.1. Top Market Strategies
• 9.2. Abbott Laboratories
  • 9.2.1. Company Overview
  • 9.2.2. Key Executives
  • 9.2.3. Company Snapshot
  • 9.2.4. Financial Performance (Subject to Data Availability)
  • 9.2.5. Product/Services Port
  • 9.2.6. Recent Development
  • 9.2.7. Market Strategies
  • 9.2.8. SWOT Analysis
• 9.3. F. Hoffmann-La Roche Ltd.
• 9.4. Thermo Fisher Scientific Inc.
• 9.5. Danaher Corporation
• 9.6. BioMerieux SA
• 9.7. QuidelOrtho Corporation
• 9.8. Siemens Healthineers AG
• 9.9. BD (Becton, Dickinson and Company)
• 9.10. Hologic, Inc.
• 9.11. PerkinElmer Inc.
• 9.12. Meridian Bioscience, Inc.
• 9.13. Luminex Corporation
• 9.14. Cepheid (a Danaher company)
• 9.15. DiaSorin S.p.A.
• 9.16. GenMark Diagnostics, Inc.